


PATENT
Docket No. 3816-4000
Facsimile

amendment can be found in Table 3 as originally filed and amended. No new matter has been added, and entry is respectfully requested.

Applicants requested the Examiner to proceed with examination with Claims 10, 28 and 31 as amended.

Respectfully submitted,



Maria C. H. Lin
Registration No. 29,323

Dated: December 6, 2001

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849
Direct line: (212) 415-8745

PATENT
Docket N 3816-4000
Facsimile

APPENDIX I
Marked-up Version of Amended Claims

Claims

10. The method according to claim 9 wherein said selection step comprise:
a first step:
- (i) binding of [the] display vehicles expressing an anti-human antigen receptor selected from the group consisting of:
 - (a) an immobilized target antigen or a fragment thereof;
 - (b) cells expressing the target human antigen or a fragment thereof, wherein the cells are optionally labelled;
 - (c) a soluble human target antigen or a fragment thereof, the human target antigen being optionally labelled;
 - (ii) removing by washing off [non-specifically binding] the display vehicles that are not bound to (a) or (b) and subsequently eluting the display vehicles that are bound to (a) or (b), and
 - (iii) positively enriching the target human antigen - bound display vehicles from the suspension of cells expressing the target human antigen (b) or from the target human antigen [in step] (c);
- the said isolated display vehicles comprising the desired anti-human antigen receptor bound to the target human antigen being optionally multiplied by replication and subjected to further rounds of in vitro selection steps (i) to (iii).
28. An anti-human antigen receptor obtained by the method according to claim 17, said anti-[target] human antigen being characterized in that it is derived from human sequences, and is specific for the native human 17-1A antigen.
31. The anti-human antigen receptor of claim 29 recognizing an epitope of the extracellular domain of the 17-1A antigen preferably comprising at least one amino acid sequence, selected from the group consisting of SEQ ID NOs: 29, 32, 34, 35, 80, 81, 98, 100.